Hereditary Motor and Sensory Neuropathy with Agenesis of the Corpus Callosum

Hereditary Motor and Sensory Neuropathy with Agenesis of the Corpus Callosum (HMSN/ACC)—also known as Andermann syndrome or ACCPN is a rare, inherited nerve and brain disorder. “Hereditary” means it runs in families. “Motor and sensory neuropathy” means the long nerves that carry movement and feeling signals are sick. “Agenesis of the corpus callosum” means the large bridge between the two brain halves did not form fully before birth.

Most people with HMSN/ACC have weakness and loss of feeling in the feet and hands that slowly worsen. They often have low muscle tone in infancy, delayed milestones, and later develop foot deformities, scoliosis, and areflexia (very low or absent reflexes). Many also have developmental delay, learning difficulties, and sometimes seizures. The condition is usually autosomal recessive. That means a child gets one non-working copy of the same gene from each parent. The main gene is SLC12A6, which builds a protein channel called KCC3. KCC3 moves potassium and chloride salts in and out of cells to keep water and volume balanced. When KCC3 does not work, nerve cells and support cells swell or shrink abnormally. Over time, the long nerve fibers are damaged. The corpus callosum also fails to form normally in the fetus.

HMSN/ACC is a rare genetic disorder that affects both the nerves of the arms and legs (motor and sensory peripheral nerves) and the connection between the two halves of the brain (the corpus callosum). Children usually have very low muscle tone and weak reflexes in the first year of life, walk late, and gradually lose strength and feeling in hands and feet. Over time, many need walking aids, then a wheelchair. Curvature of the spine (scoliosis), foot deformities, and joint tightness (contractures) are common. Thinking and learning can range from mild to severe difficulties. Some teens can have behavior changes or psychosis, and a minority have seizures. The condition is caused by two disease-causing changes (variants) in the SLC12A6 gene, which makes the K-Cl cotransporter KCC3; inheritance is autosomal recessive. There is no cure yet, but supportive care, physiotherapy, orthopedics, seizure management, and educational support improve comfort and function. NCBI

Nerve tests often show a mixed axonal and demyelinating polyneuropathy (the wires and insulation are both affected). Brain MRI shows partial or complete absence of the corpus callosum. There is no single cure yet. Care focuses on rehabilitation, orthopedic support, seizure control, assistive devices, and family genetic counseling. Early, steady therapy can greatly improve comfort, mobility, and independence.

---

Another names

HMSN/ACC has several names in the medical literature. It is widely called Andermann syndrome after the physician who described it. You may also see ACCPN (Agenesis of the Corpus Callosum with Peripheral Neuropathy). Other terms include HMSN with agenesis of the corpus callosum, SLC12A6-related neuropathy with ACC, and KCC3 deficiency. All these names point to the same core features: a hereditary sensorimotor polyneuropathy plus absent or under-developed corpus callosum. Some papers mention callosal agenesis–neuropathy complex. Older reports sometimes used broad labels like congenital callosal agenesis with neuropathy. When you see these names, check that both peripheral neuropathy and callosal agenesis are present, because other callosal disorders exist.

---

Types

1) Classic early-onset type. Symptoms start in infancy or early childhood. There is marked low tone, delayed walking, early foot deformity, and complete or near-complete callosal agenesis. Progression of weakness is steady.

2) Childhood-onset progressive type. Children walk on time but develop gait clumsiness and distal weakness in the first school years. MRI shows partial agenesis or hypogenesis of the corpus callosum. Learning difficulties may be mild to moderate.

3) Attenuated or atypical type. Weakness and numbness begin in adolescence or early adult life. Brain MRI may show a thin corpus callosum rather than full agenesis. Cognitive issues are milder, and seizures are uncommon.

4) Variant with prominent seizures or behavioral issues. The neuropathy is present, but the main problems are seizures, attention issues, or social communication difficulty. MRI confirms callosal malformation.

5) Carrier state (not a disease type). Parents who carry one faulty gene are usually healthy. This “type” is listed only to stress that carriers can have normal exams.

(Note: All “types” lie on a spectrum. The same gene can produce different severities in different people.)

---

Causes

1) Biallelic SLC12A6 loss-of-function variants. Two harmful changes—one from each parent—disable KCC3. This is the main cause of HMSN/ACC.

2) Nonsense or frameshift variants. These mutations make a very short, non-working KCC3 protein. The channel cannot move salts, so cells lose volume control.

3) Splice-site variants. These change how the gene is cut and joined. The final protein is missing key parts and fails in neurons and glia.

4) Missense variants in critical domains. A single letter change in the protein can distort the channel pore or gate. Even a small distortion can block ion flow.

5) Compound heterozygosity. Two different harmful variants, one on each gene copy, together cause the disease, even if each variant alone is rare.

6) Founder effect in certain regions. In some populations, a historical mutation became common. This raises the local disease rate in otherwise unrelated families.

7) Disrupted neuronal volume regulation. Without KCC3, neurons cannot expel chloride and water properly. Swelling or shrinkage injures axons over time.

8) Oligodendrocyte and Schwann cell stress. Myelin-forming cells also need KCC3. Their dysfunction leads to mixed demyelination and axonal damage.

9) Axonal transport failure. Sick axons move cargo poorly. Energy and building blocks do not reach the long nerve ends, so distal nerves degenerate first.

10) Wallerian-type degeneration. Once axons are hurt, they break down from the far end back toward the cell body, causing length-dependent neuropathy.

11) Developmental guidance errors in the forebrain. Proper ion balance is needed while the fetal brain builds midline tracts. Without KCC3, callosal axons fail to cross.

12) Secondary inflammation. Chronic axonal injury can trigger small, long-term inflammatory responses that worsen nerve damage.

13) Mitochondrial stress under ion imbalance. Constant pumping to correct ion errors burns energy. Neuronal mitochondria tire and produce harmful by-products.

14) Cytoskeletal instability. Abnormal cell volume strains microtubules and neurofilaments, making axons fragile.

15) Synaptic signaling changes. Chloride levels affect inhibitory signals. Abnormal inhibition can shape circuits poorly, linking to seizures or behavior issues.

16) Modifier genes. Other genetic differences can make disease more or less severe, explaining variability within families.

17) Epigenetic factors. Gene activity patterns during development may shift severity without changing DNA sequence.

18) Perinatal stress as a severity modifier. Prematurity or early illness does not cause HMSN/ACC but can add extra stress to vulnerable nerves and brain.

19) Nutritional deficiencies as confounders. Low B12 or thyroid disease does not cause HMSN/ACC but can mimic or worsen neuropathy and should be treated.

20) Mechanical strain from skeletal deformity. Over years, scoliosis and foot deformities add mechanical stress to already weak nerves and muscles, deepening disability.

---

Symptoms

1) Low muscle tone in infants. Babies feel “floppy.” They hold their head late and have trouble rolling or sitting.

2) Delayed milestones. Standing and walking come later than usual. Some children need braces or walkers.

3) Distal muscle weakness. Ankles and hands are weakest. Toes catch the ground, and fine finger work is hard.

4) Foot deformities (pes cavus / hammer toes). Tight, high arches and curled toes develop as muscles lose balance.

5) Gait problems and tripping. Foot drop and weak ankles cause frequent stumbles and slow walking.

6) Sensory loss. Numbness begins in the feet, then the hands. Vibration and position sense fade first.

7) Areflexia. Knee and ankle jerks are weak or absent because the nerve loop is damaged.

8) Muscle wasting. Calf and hand muscles thin over time, making bony outlines more visible.

9) Scoliosis. The spine curves as trunk muscles weaken and grow unevenly.

10) Hand dysfunction. Grip is weak. Buttons, zippers, and handwriting become difficult.

11) Fatigue. Extra effort to move weak muscles causes tiredness after short activity.

12) Developmental and learning difficulties. The missing or thin corpus callosum makes coordination of brain halves harder, affecting learning speed and problem-solving.

13) Speech and language delay. Words may come late, and complex language can be challenging.

14) Seizures (in some). Abnormal brain wiring and signaling raise the risk of seizures in a subset of people.

15) Autonomic or bladder issues (in some). Dizziness on standing, poor sweating, or urinary urgency may appear as neuropathy progresses.

---

Diagnostic tests

A) Physical examination (bedside clinical assessment)

1) General neurologic exam. The clinician checks tone, power, feeling, coordination, and reflexes. In HMSN/ACC there is low tone, distal weakness, sensory loss, and areflexia.

2) Developmental assessment. Motor, speech, and social milestones are reviewed with age-matched scales. Delays support the diagnosis and guide therapy goals.

3) Gait and posture analysis. Walking pattern, step height, and balance are observed. Foot drop and scoliosis become clear during this exam.

4) Cranial nerve exam. Eye movements, facial strength, and swallow are checked. Findings are usually mild, but they help exclude other diseases.

5) Musculoskeletal survey. The clinician inspects for pes cavus, hammer toes, contractures, and spinal curve. These findings support a chronic neuropathy picture.

B) Manual tests (simple tools at the bedside)

6) Manual muscle testing (MMT). Strength is graded by hand pressure (0–5 scale). Distal muscles score lower than proximal muscles in HMSN/ACC.

7) Vibration testing with a tuning fork. A 128-Hz tuning fork on toes and fingers checks large-fiber sensation. Reduced vibration sense is common.

8) Proprioception and Romberg test. With eyes closed, standing balance is tested. Wobbling or falling suggests joint-position sense loss.

9) Pinprick and light touch mapping. A sterile pin and cotton gauge small-fiber and large-fiber feeling. Stocking-and-glove loss supports polyneuropathy.

10) Deep tendon reflex testing. The reflex hammer tests ankle and knee jerks. Absent or very low responses are typical in HMSN/ACC.

C) Laboratory and pathological tests

11) Genetic testing for SLC12A6. Sequencing and copy-number analysis look for two harmful variants. A positive result confirms the specific diagnosis and enables family counseling.

12) Expanded gene panel or exome. If the first test is unclear, broader testing checks many neuropathy and brain-malformation genes to rule out mimics.

13) Basic metabolic and nutritional labs. B12, methylmalonic acid, thyroid, glucose, and autoimmune screens do not diagnose HMSN/ACC but rule out add-on causes of neuropathy.

14) Nerve biopsy (rarely needed now). Older practice used a small sural nerve sample to show axonal loss and demyelination. Today, genetics usually replaces biopsy.

15) CSF studies (selective). Spinal fluid is seldom needed. It may be done if inflammation or infection is suspected. In HMSN/ACC, CSF is usually normal.

D) Electrodiagnostic tests

16) Nerve conduction studies (NCS). Surface electrodes measure speed and size of nerve signals. HMSN/ACC often shows slow speeds (demyelination) and low amplitudes (axonal loss).

17) Electromyography (EMG). A fine needle measures muscle electrical activity. It shows chronic denervation and reinnervation, confirming a length-dependent neuropathy.

18) Somatosensory evoked potentials (SSEPs). Small skin shocks and scalp recordings test long sensory pathways. Delays reflect damaged large fibers and brain connectivity.

19) Electroencephalogram (EEG). If seizures or staring spells occur, EEG looks for abnormal rhythms. It helps choose anti-seizure medicines safely.

E) Imaging tests

20) Brain MRI with midline views and tractography when available. MRI shows partial or complete agenesis of the corpus callosum, colpocephaly (back-of-brain ventricles look widened), Probst bundles (misrouted fibers), and sometimes a thin brainstem. Advanced imaging can map missing callosal tracts. Spine MRI helps plan scoliosis care.

Non-pharmacological treatments

Below are physiotherapy approaches and 10 mind-body / gene-informed / educational supports. Each includes description, purpose, mechanism, and benefits in simple English.

Physiotherapy

1. Early, continuous physiotherapy – Begin at diagnosis and continue lifelong. Purpose: maintain mobility and delay loss of function. Mechanism: task-specific practice (sitting, standing, transfers), strengthening without over-fatigue, balance training. Benefits: safer mobility, fewer falls, slower contracture formation. NCBI

2. Stretching program – Daily gentle stretches for calves, hamstrings, hip flexors, and finger flexors. Purpose: prevent contractures. Mechanism: sustained low-load stretch remodels connective tissue. Benefits: easier standing, brace fitting, and hygiene. NCBI

3. Ankle-foot orthoses (AFOs) – Custom braces to stabilize weak ankles/feet. Purpose: improve foot clearance and alignment. Mechanism: external support substitutes for weak muscles. Benefits: safer walking and reduced falls. NCBI

4. Hand/wrist splints – Night splints for MCP flexion contractures and daytime functional splints. Purpose: preserve grasp and hygiene. Mechanism: positions joints to minimize shortening. Benefits: slower deformity and better hand use. NCBI

5. Gait training with aids – Walkers, reverse walkers, or canes as strength declines. Purpose: prolong ambulation. Mechanism: wider base and weight transfer support. Benefits: independence and reduced fatigue. NCBI

6. Balance and trunk control drills – Static/dynamic balance, core activation, and postural re-education. Purpose: prevent falls and scoliosis aggravation. Mechanism: improves motor planning and postural responses. Benefits: steadier transfers and walking. NCBI

7. Strengthening (submaximal) – Focus on proximal muscles and endurance with low-resistance, many-reps; avoid overwork. Purpose: keep muscles active safely. Mechanism: neural recruitment without axonal overuse. Benefits: function maintained longer. NCBI

8. Task-specific mobility practice – Sit-to-stand, bed mobility, wheelchair skills. Purpose: real-world independence. Mechanism: motor learning and repetition. Benefits: easier daily care. NCBI

9. Respiratory physiotherapy (when indicated) – Breathing exercises and assisted cough if restrictive pattern from scoliosis. Purpose: protect lungs. Mechanism: improves ventilation and secretion clearance. Benefits: fewer infections. NCBI

10. Aquatic therapy – Buoyancy supports weak muscles for safe practice. Purpose: conditioning with low joint stress. Mechanism: graded resistance from water. Benefits: endurance and confidence. (General PT principle—appropriate for neuromuscular weakness.)

11. Standing frames / supported standing – For those who cannot stand safely alone. Purpose: bone health, hip alignment, bowel/bladder function. Mechanism: weight-bearing stimulus. Benefits: comfort and fewer contractures. FAST

12. Wheelchair seating and positioning – Custom seating, lateral trunk supports, headrests. Purpose: reduce scoliosis progression discomfort and pressure sores. Mechanism: optimal posture and pressure distribution. Benefits: comfort, safety, and communication access. NCBI

13. Orthotic shoe/footwear management – Rocker soles, custom insoles. Purpose: optimize gait mechanics. Mechanism: compensates for weak push-off and deformity. Benefits: fewer falls and pain. NCBI

14. Home exercise & caregiver training – Teach daily routines, safe transfers, and monitoring red flags. Purpose: continuity between clinic and home. Mechanism: repetition and environmental fit. Benefits: fewer admissions and better quality of life. NCBI

15. Fall-prevention & environmental adaptations – Remove trip hazards, add rails, adjust bathroom. Purpose: safety. Mechanism: reduces external risks. Benefits: fewer injuries. (Widely recommended in progressive mobility disorders.)

Mind-body, gene-informed, and educational therapies

16. Individualized Education Plan (IEP) – Tailored goals for reading, numeracy, daily living skills; consider assistive tech and extra time. Purpose: maximize learning. Mechanism: matches teaching style to cognitive profile. Benefits: better school progress and independence. NCBI

17. Speech-language therapy – For articulation and pragmatic language; augmentative/alternative communication if needed. Purpose: clearer communication. Mechanism: motor speech practice and language scaffolding. Benefits: participation and safety. (Education/rehab standard.)

18. Occupational therapy (OT) – Fine motor, adaptive equipment, writing aids, self-care training. Purpose: daily independence. Mechanism: task adaptation and energy conservation. Benefits: confidence and function. NCBI

19. Behavioral health care – Screening for anxiety/depression; early referral if psychosis appears in adolescence. Purpose: mental well-being. Mechanism: CBT/psychotherapy and coordinated psychiatric care. Benefits: safety and family support. NCBI

20. Family genetic counseling – Explains autosomal recessive inheritance (25% recurrence risk) and options (carrier, prenatal, or preimplantation testing). Purpose: informed family planning. Mechanism: DNA-based counseling. Benefits: clarity and planning. NCBI

21. Mindfulness/relaxation training – Breathing, guided imagery, relaxation for pain/anxiety. Purpose: symptom control. Mechanism: reduces central pain amplification and stress hormones. Benefits: better sleep, coping. (General chronic pain evidence.)

22. Sleep hygiene program – Fixed schedule, light control, screen limits. Purpose: stabilize energy and mood. Mechanism: circadian entrainment. Benefits: daytime function.

23. Nutrition counseling – Balanced calories, calcium/vitamin D, protein for muscle. Purpose: maintain weight/strength. Mechanism: supports bone and muscle in low-activity states. Benefits: fewer pressure sores and fractures.

24. Community mobility & access planning – Transport training, school/work accessibility. Purpose: participation. Mechanism: barrier removal. Benefits: quality of life.

25. Research engagement (gene-informed) – Discuss clinical trials/registries; no approved gene therapy yet, but KCC3 biology suggests future KCC3-targeted approaches. Purpose: awareness. Mechanism: links families to evolving science. Benefits: informed choices. Physiological Journals

---

Drug treatments

There is no disease-modifying drug proven for HMSN/ACC. Medicines below treat symptoms such as neuropathic pain, seizures, mood/behavior issues, sleep problems, and musculoskeletal discomfort. Doses are typical starting ranges for adults unless noted; dosing must be individualized.

1. Gabapentin (antiepileptic, neuropathic pain) – Class: gabapentinoid. Typical start 100–300 mg at night; titrate to 900–3600 mg/day in 3 doses. Purpose: neuropathic pain/sleep. Mechanism: binds α2δ calcium channel subunit, reducing excitatory neurotransmission. Side effects: dizziness, somnolence, edema. Strong guideline support as first-line for neuropathic pain. PMCScienceDirect

2. Pregabalin (gabapentinoid) – Start 25–75 mg at night; usual 150–300 mg/day in 2–3 doses (max 600 mg/day). Purpose: neuropathic pain/anxiety/sleep. Mechanism: α2δ modulation; rapid onset. Side effects: dizziness, weight gain, edema. Guideline-endorsed first-line. ScienceDirectPMC

3. Duloxetine (SNRI) – 30 mg daily, increase to 60 mg daily. Purpose: neuropathic pain and low mood. Mechanism: enhances descending pain inhibition via serotonin/norepinephrine. Side effects: nausea, dry mouth, BP changes. First-line for neuropathic pain. ScienceDirect+1

4. Amitriptyline (TCA) – 10–25 mg at night; titrate to 25–75 mg. Purpose: neuropathic pain/sleep. Mechanism: serotonin/norepinephrine reuptake block, anticholinergic effects. Side effects: dry mouth, constipation, QT risk—use caution. First-line option in many guidelines. Lippincott Journals

5. Topical lidocaine 5% patches – 12 h on/12 h off to focal painful areas (if present). Purpose: local pain without systemic effects. Mechanism: sodium channel block. Side effects: local rash. Second-line/add-on in neuropathic pain guidance. Lippincott Journals

6. Capsaicin 8% patch (clinic-applied) – Single 30–60 min application; repeat every 2–3 months if benefit. Purpose: focal neuropathic pain. Mechanism: TRPV1 desensitization of nociceptors. Side effects: local burning. Guideline-supported for painful peripheral neuropathy. Diabetes Journals

7. Tramadol (weak opioid/SNRI) – 25–50 mg as needed, max 400 mg/day; short term only. Purpose: rescue for severe neuropathic pain when first-line drugs fail. Mechanism: μ-opioid + monoamine effects. Side effects: nausea, dizziness, dependence risk. Reserve use. Lippincott Journals

8. Valproate (anti-seizure; behavior aid) – 250 mg twice daily and titrate by levels/response. Purpose: seizures and sometimes behavioral stabilization. Mechanism: GABA enhancement, multiple channels. Side effects: weight gain, liver/pancreas risks; avoid in pregnancy. Mentioned for ASM and behavior in HMSN/ACC. NCBI

9. Levetiracetam (anti-seizure) – 250–500 mg twice daily; titrate. Purpose: seizure control with simpler interactions. Mechanism: SV2A modulation. Side effects: mood irritability, somnolence. Standard ASM option. NCBI

10. Risperidone or quetiapine (atypical antipsychotics) – Low dose titrated by psychiatry. Purpose: adolescent psychosis. Mechanism: dopaminergic/serotonergic modulation. Side effects: weight/metabolic effects, sedation—monitor. Neuroleptics may be needed in HMSN/ACC. NCBI

11. Melatonin (sleep) – 1–3 mg 1–2 hours before bedtime. Purpose: sleep onset. Mechanism: circadian support. Side effects: morning grogginess.

12. Acetaminophen/NSAIDs – Doses per standard labels. Purpose: musculoskeletal pain from deformities or surgery recovery (not neuropathic pain). Side effects: GI, renal, hepatic cautions.

13. Botulinum toxin A (focal tone/pain) – Injected into overactive muscles if focal dystonia/painful postural imbalances occur; case-by-case in rehab. Purpose: reduce pain and improve seating/gait. Side effects: local weakness. (General pain/spasticity tool; not disease-specific.)

14. Baclofen or tizanidine (only if true spasticity) – Start very low (e.g., baclofen 5 mg at night; tizanidine 2 mg at night) and titrate if spasticity is objectively present; many HMSN/ACC patients are hypotonic and do not need these. Side effects: sedation, weakness, liver effects (tizanidine). Use cautiously and only if exam confirms spasticity. Wiley Online LibraryMedscape

15. Topical analgesic creams (e.g., menthol) – Adjunct for localized discomfort in feet/ankles. Purpose: transient symptom relief. Mechanism: counter-irritation. Side effects: skin irritation.

Strong neuropathic pain guidance supports gabapentin, pregabalin, duloxetine, and amitriptyline as first-line; topical agents and tramadol are second-line options. Adapt choices to age, comorbidities, and interactions. ScienceDirectPMCLippincott Journals

---

Dietary molecular supplements

Supplements are adjuncts; confirm interactions and labs with your clinician.

1. Alpha-lipoic acid (ALA) – 600 mg/day (oral; some use short IV courses under supervision). Function: antioxidant, improves nerve blood flow and oxidative stress. Evidence from meta-analyses suggests symptom benefit in diabetic neuropathy; quality varies. Mechanism: Nrf2 activation, reduces lipid peroxidation. Side effects: GI upset, rare hypoglycemia. PMC+1

2. Acetyl-L-carnitine (ALC) – 1,000–2,000 mg/day divided. Function: mitochondrial support and nerve regeneration. Evidence: RCTs/meta-analyses show moderate pain reduction in peripheral neuropathies. Side effects: nausea, rare restlessness. PMCPLOS

3. Benfotiamine (vitamin B1 derivative) – 300–600 mg/day. Function: reduces advanced glycation; studied mainly in diabetic neuropathy; mixed evidence but signals for symptom relief. Side effects: generally well tolerated. diabetesresearchclinicalpractice.comAlzheimer’s Drug Discovery Foundation

4. Vitamin D – Dose guided by blood levels (often 800–2000 IU/day; correct deficiency per clinician). Function: neuromodulation and inflammation control; early studies show pain improvement when deficient. Side effects: hypercalcemia if overdosed. jns-journal.comPMC

5. Omega-3 (EPA/DHA) – 1–2 g/day combined EPA+DHA. Function: anti-inflammatory/neuroprotective; small trials suggest benefit in chemotherapy or diabetic neuropathy settings. Side effects: fishy taste, bleeding risk on high doses. Diabetes JournalsBioMed Central

6. Vitamin B12 (if low) – Oral high-dose or IM per labs. Function: myelin/nerve health. Mechanism: cofactor in methylation pathways. Side effects: minimal. (Standard neuropathy care when deficient.)

7. Coenzyme Q10 – 100–200 mg/day. Function: mitochondrial antioxidant; limited but plausible support in neuropathic pain settings. Side effects: GI upset. (Adjunct evidence modest.)

8. Magnesium (if low) – 200–400 mg elemental/day. Function: nerve excitability modulation and muscle relaxation. Side effects: diarrhea; adjust dose.

9. Curcumin (enhanced bioavailability) – According to product (often 500–1000 mg/day). Function: NF-κB modulation; small neuropathy studies suggest symptom relief; evidence preliminary. Side effects: GI upset, drug interactions.

10. N-acetylcysteine (NAC) – 600–1200 mg/day. Function: glutathione support/antioxidant; exploratory data in neuropathic pain; consider if oxidative stress high. (Evidence early.)

Immunity-booster / regenerative / stem-cell” therapies

Important: HMSN/ACC is not an immune disease, and there are no approved immune boosters, stem-cell drugs, or gene therapies for this condition. What follows are research directions only; access is usually limited to clinical trials.

1. AAV-based gene replacement for SLC12A6 (preclinical) – Concept: deliver a healthy SLC12A6 copy to neurons. Mechanism: restore KCC3 function. Status: AAV is widely used in neuro gene therapy research; specific HMSN/ACC trials have not started. BioMed CentralMDPI

2. CRISPR/base-editing of SLC12A6 (preclinical) – Concept: correct pathogenic variants in patient cells. Mechanism: precise gene repair. Status: theoretical for HMSN/ACC; would require disease-specific development. (General CRISPR neurotherapeutics literature.)

3. Patient-derived iPSC models – Concept: create neurons/Schwann cells from patient cells to test drugs that modulate KCC3 pathways. Mechanism: disease-in-a-dish screening. Status: research platform, not therapy yet. PMC

4. Schwann cell/MSC approaches for peripheral nerve repair – Concept: transplant supportive cells or use their exosomes to release growth factors and guide axon repair. Status: promising in peripheral nerve injury; neuropathic pain/MSCs under study; not established for HMSN/ACC. BioMed CentralFrontiers

5. Neurotrophic factor delivery (e.g., NT-3/BDNF vectors) – Concept: enhance axonal survival and myelination. Status: explored in peripheral nerve repair research; not HMSN/ACC-specific. Frontiers

6. KCC3 pathway pharmacology – Concept: small molecules that increase residual KCC3 function or compensate via related transporters. Status: target biology reviewed; no approved drug yet. Taylor & Francis Online

---

Surgeries

1. Spinal fusion for scoliosis – Straightens and stabilizes a progressive curve that affects sitting balance and lung function. Done when curves pass surgical thresholds or braces fail. Goal: better posture, pain control, and pulmonary mechanics. NCBI

2. Foot/ankle corrective surgery – Procedures tailored to valgus/varus deformity, tendon transfers, or osteotomies to improve foot alignment and shoe/brace fit; often combined with orthotics. NCBI

3. Achilles tendon lengthening – Releases tight heel cord to allow flat-foot stance and brace fitting, reducing falls and pain. NCBI

4. Contracture releases (hand/wrist/fingers) – Improves hygiene and function when splints and therapy no longer suffice. NCBI

5. Hardware/orthopedic revisions as needed – For growth changes or hardware problems; keeps alignment and comfort optimized. NCBI

---

Prevention tips

1. Regular PT/OT and stretching to delay contractures.

2. Early scoliosis monitoring with scheduled spine checks. NCBI

3. Fall-proof home (rails, lighting, remove loose rugs).

4. Vaccinations and respiratory hygiene to reduce lung infections when scoliosis/weakness limit breathing reserve.

5. Healthy weight and bone care (calcium, vitamin D, weight-bearing as able).

6. Foot care (proper shoes, daily inspection) to prevent pressure sores in numb feet.

7. Sleep routine to stabilize energy and mood.

8. Skin care and pressure-relief cushions for wheelchair users.

9. Mental health check-ins—rapid referral for new hallucinations/paranoia in adolescence. NCBI

10. Genetic counseling for families planning more children. NCBI

---

When to see doctors urgently vs. routinely

• Urgently: new or worsening breathing problems, rapid curve progression with pain, repeated falls, sudden behavior change/psychosis, new seizures, fever with chest symptoms, unhealing foot sores. NCBI

• Routinely: scheduled neuro/rehab visits, orthopedics for spine/feet, PT/OT reviews, educational planning meetings, mental health follow-ups, and genetics appointments. NCBI

---

What to eat and what to avoid

Eat more of: balanced meals with lean protein (muscle support), fruits/vegetables (micronutrients/antioxidants), whole grains (energy), dairy/fortified alternatives (calcium/vitamin D), and healthy fats (omega-3 rich fish such as sardines/salmon). Adequate fluids and fiber help bowel function in low mobility.

Limit/avoid: ultra-processed foods, excess added sugar, very high salt, and large amounts of alcohol (worsens neuropathy and falls). If on interacting medicines (e.g., valproate), avoid unapproved herbal combos—check first with the care team.

---

Frequently asked questions (FAQ)

1. Is HMSN/ACC the same as Andermann syndrome?
   Yes—different names for the same condition. NCBI

2. What gene is involved?
   SLC12A6, which encodes the K-Cl cotransporter KCC3. Two faulty copies are needed (autosomal recessive). NCBI

3. When do symptoms start?
   Infancy: low tone, absent reflexes, late motor milestones; walking often begins around 3–4 years and is lost in early teens. NCBI

4. What brain finding is typical?
   Complete or partial agenesis of the corpus callosum on MRI (though a minority have a normal callosum). NCBI

5. Do all patients have learning problems?
   No. Intelligence ranges from normal to severe disability; early educational support is vital. NCBI

6. Are seizures common?
   They occur in a minority; standard anti-seizure medicines are used. NCBI

7. Why scoliosis and foot deformities?
   Progressive muscle weakness and imbalance alter posture and growth; many need orthoses and sometimes surgery. NCBI

8. Is there specific medicine to stop the disease?
   Not yet. Care focuses on symptom control, function, and prevention of complications. NCBI

9. What about stem cells or gene therapy?
   Promising research exists in peripheral nerve repair and gene delivery fields, but no approved therapy for HMSN/ACC today. Beware unregulated clinics. BioMed CentralBioMed Central

10. Which pain medicines work best?
    Guidelines favor duloxetine, amitriptyline, gabapentin, or pregabalin to start; topical agents or tramadol can be add-ons if needed. Choice depends on age and comorbidities. ScienceDirectPMC

11. How long do braces and therapy help?
    They delay problems and keep function longer, even if the condition progresses. Consistency is key. NCBI

12. What is the life expectancy?
    It varies; historical series report an average in the early 30s, often related to respiratory complications. Modern supportive care may improve outcomes, but robust data are limited. NCBI

13. Can family members be tested?
    Yes—once the family’s SLC12A6 variants are known, relatives can access carrier and prenatal/PGT testing. NCBI

14. What specialists should be involved?
    Neurology, physiatry (rehab), physiotherapy/OT/speech, orthopedics, mental health, pulmonology (if needed), genetics, and nutrition. NCBI

15. Where can I read a concise medical summary?
    See GeneReviews and MedlinePlus Genetics for reliable overviews of features, testing, and management. NCBIMedlinePlus

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 10, 2025.

PDF Documents For This Disease Condition References